Carrick in the dark over his future ahead of week of reckoning at Man United

With Manchester United on its worst run of results in nearly 40 years, Michael Carrick isn’t looking beyond the upcoming week amid fevered speculation about his future.

Carrick is limping on as United manager amid a nine-game winless streak in all competitions that has featured desperate performances, critical post-match outbursts and audible fan disgruntlement toward the team's underperforming players.

A two-week international break, starting next Monday, is fast approaching and looks an ideal time for United to make decision on whether Carrick is still the man for the job.

Before then, United plays Roma in the Champions League on Tuesday and Aston Villa in the Premier League on Sunday.

“I don't know what’s going to happen,” said Carrick, sounding very much like someone not in charge of his own destiny.

Whatever happens, Carrick wants to go out with a bang — beginning with the visit of Roma in a fixture that holds sweet memories for him. Back in 2007, when United was one of Europe's top teams and Carrick was bestriding its midfield, he scored twice in a 7-1 rout of the Italian club in the second leg of the Champions League quarterfinals.

No wonder some enthusiasm was heard in his voice ahead of the game at Old Trafford.

“You may think I’m crazy with the results we’ve had and what’s going on,” Carrick said, “but I genuinely really can't wait for the game tomorrow. That is what I’m focused on. I really am.

“Whatever happens is going to happen after that, in whatever direction it goes in. But we want to make it a big night tomorrow night first.”

Carrick said the United locker room “is a good place,” despite the club's longest winless run since 1988 and the fact that the once-feared Red Devils are in 17th place in the Premier League — only out of the relegation zone on goal difference — and 20th in the 36-team Champions League standings.

“The commitment of the players to the club, to me, to each other, I don’t question that at all,” Carrick said. “We need to play better, we can make better decisions, but the commitment is not a thing at all.”

Nowhere is the scrutiny stronger than on Lisandro Martinez, the Argentina defender who blasted club officials in media interviews after last month's Champions League loss at Atletico Madrid and then collected two yellow cards in four minutes in an act of self-destruction that led to United losing 2-0 at Chelsea on Saturday.

Carrick refused to even look at Martinez as the defender walked off the field following his red card. Yet, it doesn't appear he has given up on him just yet.

“I've got no concerns about the commitment at all,” Carrick said of Martinez. “Things happen in football — sometimes you do things, sometimes you make a decision, sometimes you make mistakes, sometimes it goes well for you. The commitment is not an issue for sure.”

See AP’s full soccer coverage here

Referee Peter Bankes shows a red card to Manchester United's Lisandro Martinez (6) during the English Premier League soccer match between Chelsea and Manchester United in London, Saturday, Oct. 31, 2026. (AP Photo/Ian Walton)

Manchester United's head coach Michael Carrick follows the game during the English Premier League soccer match between Chelsea and Manchester United in London, Saturday, Oct. 31, 2026. (AP Photo/Ian Walton)

Manchester United manager Michael Carrick attends a training session in Manchester, England, Monday Nov. 2, 2026. (Martin Rickett/PA via AP)

Manchester United's head coach Michael Carrick, center, reacts during the English Premier League soccer match between Chelsea and Manchester United in London, Saturday, Oct. 31, 2026. (AP Photo/Ian Walton)

The U.S. Food and Drug Administration has approved a generic version of the world’s only twice-a-year shot to prevent HIV — a big step toward making the drug available inexpensively and more quickly in 120 low- and middle-income countries.

The announcement was made on Monday morning by the manufacturer and organizations that helped to speed up development of the medication, called lenacapavir.

The drug is expected to cost $40 a year per person in the countries where it will be available, the same price as daily preventive pills available now. But the shots are much more convenient than the pills because they’re needed much less frequently and they nearly eliminated new infections in two groundbreaking studies of people at high risk.

People don’t always take their daily dose of medication, “and if you do not take it, you cannot get protected against HIV,” said Carmen Pérez Casas, HIV lead for the grant-making organization Unitaid, a global health agency. “With lenacapavir, we are much more hopeful.”

Ultimately, advocates said, the medication should help drive down cases of HIV and AIDS — and deaths. According to the World Health Organization, 41 million people worldwide were living with HIV and 570,000 died from HIV-related causes last year.

With an affordable, high-quality generic medication now available, “we could help to scale this to the 20 million people around the world who need PrEP,” prescription medicine taken by people at risk of HIV before being exposed to the virus, said Carolyn Amole, who leads the HIV program for the Clinton Health Access Initiative, a global health organization.

“And if we scale to those levels,” she added, “we can actually begin to bring an end to the HIV epidemic.”

Generic lenacapavir can’t be sold in the U.S. because a brand-name version, Yeztugo, made by Gilead Sciences and approved last year, is still protected by a patent. The U.S. list price for that version, meaning the cost before insurance, is $28,218 a year. Gilead officials say that’s similar to some other types of PrEP, which stands for pre-exposure prophylaxis.

The new generic was approved by the FDA under a longstanding practice designed to ensure the quality of HIV-related drugs provided to other countries by the U.S. government. Approval of a drug by the U.S. FDA can speed regulatory approval in many other countries. The approval is considered “tentative,” the FDA's standard designation for generics while the originator remains under patent.

Until now, Gilead has been the sole supplier of lenacapavir, and demand has outstripped supply in low- and middle-income countries. Last year, Gilead established royalty-free licensing agreements with six generic manufacturers to enable production. Those voluntary licenses cover a specific set of countries in sub-Saharan Africa, Asia and Latin America.

“We share the sense of urgency around expanding access to lenacapavir for HIV prevention,” a Gilead spokesperson said in a statement. “We believe we have enabled the fastest and most sustainable path to expanding access for communities most affected by HIV.”

The generic was developed by India-based Dr. Reddy’s Laboratories under an agreement brokered by Unitaid, the Clinton Health Access Initiative and Wits RHI, a health research institute in Africa. The partners sought to accelerate development and make the drug available at an affordable price.

Common side effects with lenacapavir include injection site reactions, headache and nausea. People also must be tested for HIV prior to starting the drug and with each injection; drug-resistant HIV has been identified when used by people with an undiagnosed HIV infection.

“For any kind of PrEP … you need to have HIV testing in advance,” said Saiqa Mullick, director of implementation science with Wits RHI. “For many of the low- and middle-income countries, that is a rapid test.”

Generic lenacapavir should start to become available in some places within weeks, those helping with the effort said, although it could take a bit longer in countries that require the drug to go through their own approval processes before people can start taking it. Generic versions made by the other manufacturers have yet to be approved by FDA.

“The work is not done. Now, we need the funding to actually buy it for everyone who needs it and then we need to do the hard work of getting it to the millions of people who need it and want it,” Amole said. “But this is a great milestone.”

Casas said she’s optimistic that scientific advances — along with political will and funding — can help the world curb HIV.

“Now,” she said, “we have the tools.”

Gerald Imray in Cape Town, South Africa, contributed to this story.

The Associated Press’ health and science coverage receives financial support from the AP Fund for Journalism and private foundations. AP is solely responsible for all content. Find AP’s standards for working with philanthropies, a list of supporters and funded coverage areas at AP.org.

FILE - The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, April 22, 2025. (AP Photo/Jose Luis Magana, File)